Spine Fusion Instrumented With BMP-2 vs Uninstrumented With Infuse BMP-2 Alone
NCT ID: NCT00405600
Last Updated: 2013-02-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
50 participants
INTERVENTIONAL
2006-11-30
2010-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
In this research study, bone graft substitute material called Bone Morphogenetic Protein-2 known as BMP-2 Infuse will be used. No hip bone will be used. The surgical procedure will consist of BMP-2 Infuse with or without the use of rods and screws.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Pilot Study of rhBMP-2/ACS/Allograft Bone Dowel for Anterior Lumbar Interbody Fusion in Patients With Symptomatic Degenerative Disc Disease
NCT01494428
Natural Matrix Protein
NCT07217964
A Multi-center, Comparative Clinical Trial to Evaluate the Efficacy and Safety of Inject BMP in Patients Undergoing Transforaminal Lumbar Interbody Fusion
NCT02504242
Pilot Study of rhBMP-2/ACS/LT-CAGE® for Anterior Lumbar Interbody Fusion in Patients With Degenerative Disc Disease
NCT01491373
Pilot Study of rhBMP-2/BCP in Patients With Spinal Degeneration With Instability Requiring Surgical Fusion
NCT01495234
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Currently, the acceptable standard of care for spinal fusion surgery requires instrumented or non-instrumented procedure with the use of bone graft materials, to facilitate bone growth, and a fusion, thus eliminating movement between the inciting vertebrae.
In this study, the surgical procedure will be BMP-2 Infuse with instrumentation or BMP-2 Infuse alone.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Device
Device used in surgery with or without instrumentation
Device used in surgery with or without instrumentation
Infuse Bone Graft BMP-2, Large Kit will be used in all surgeries. Spine surgeries will be either instrumented or uninstrumented.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Device used in surgery with or without instrumentation
Infuse Bone Graft BMP-2, Large Kit will be used in all surgeries. Spine surgeries will be either instrumented or uninstrumented.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient signed informed consent.
* Patient is willing to be available for each examination scheduled over the study duration.
* Patient has clinical and radiologic history of degenerative disc disease or spondylolisthesis (no greater than grade 1 utilizing Meyerding's classification (Meyerding HW, 1932)); spinal stenosis for which conservative treatment has failed and lumbar spinal fusion is indicated.
* Eligible for non-instrumented or instrumented surgical procedure
* Has one or two levels (contiguous) involvement from L1-S1 requiring fusion
* Has preoperative Oswestry score greater than 30
* Has not responded to non-operative treatment for a period of 6 months (bed rest, physical therapy, medication, manipulations, spinal injections, other).
* Is at least 20 years of age inclusive at the day of surgery
* If female of childbearing potential, patient is non-pregnant, non-nursing, and agrees to use adequate contraception for one year following surgery.
Exclusion Criteria
* Patient has had more than one previous non-fusion spinal surgery at the involved level.
* Patient requires fusion at more than 2 levels.
* Patient has pseudoarthroses from a previous fusion attempt.
* Patient has highly communicable diseases, inflammatory or autoimmune disease (e.g.osteomyelitis, crohn's, rheumatoid arthritis, systemic lupus, gout, HIV/AIDS, active tuberculosis, venereal disease, active hepatitis). A note to file written by the investigator will permit a patient into the study who experiences a mild case which will not affect the outcome of the study.
* Has been previously diagnosed with osteopenia, osteoporosis, or osteomalacia to a degree that spinal instrumentation would be contraindicated
* Patient has a significant medical history that, in the Investigator's opinion would not make them a good study candidate.
* Patient requires interbody cage fusion or non-pedicle screw instrumentation.
* Pregnancy.
* Has presence of active malignancy (except basal cell carcinoma of the skin)
* Has a history of severe allergy (anaphylaxis)
* Is grossly obese, i.e. weight over 40% over ideal for their height and age.
* Has a fever (temperature over 101 F oral)
* Has an allergy to the BMP-2
* Has allergy to bovine products
* Has an allergy to collagen implants
* Is mentally incompetent(if questionable, obtain psychiatric consult)
* Is a prisoner, a transient or have been treated in an inpatient substance abuse program for alcohol and/or drug abuse within six months prior to proposed study enrollment.
* Has received drugs which may interfere with bone metabolism within two weeks prior to the planned surgery
* Has a diagnosis, which requires postoperative medication that interferes with fusion, such as steroids.
* Has history of endocrine or metabolic disorder known to affect osteogenesis (e.g. Paget's disease, renal osteodystrophy, Ehlers-Danios syndrome or osteogenesis imperfecta)
20 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Nova Scotia Health Authority
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
David Alexander
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Dr. David Alexander, M.D.
Role: PRINCIPAL_INVESTIGATOR
Capital Health District Authority, Centre for Clinical Research, Queen Elizabeth II, Health Sciences Centre, 1278 Tower Rd.,Halifax, Nova Scotia, B3H-9Z9, Canada
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Capital Health Health Authority, QEII Health Sciences Centre, Halifax Infirmary site,
Halifax, Nova Scotia, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CDHA016
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.